IP Library Granted Patent US 10,697,961
Granted Patent B2
US 10,697,961 · App. 15/161,024 · Granted Jun 30, 2020

Methods for predicting post-operative recurrence of Crohn's disease

Inventors: Steven Lockton (San Diego, CA); Marc Ferrante (Leuven, BE); Severine Vermiere (Leuven, BE); Sharat Singh (Rancho Santa Fe, CA)
Assignees: Prometheus Biosciences, Inc.; Katholieke Universiteit Leuven
G01N33/564G01N2800/065G01N2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,697,961
App. No.
15/161,024
Granted
Jun 30, 2020
Kind
B2
Abstract

The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.

Claims (27)

1. A method for predicting post-operative recurrence of Crohn's disease (CD) in a subject with CD that is undergoing or planning on undergoing surgical treatment of the CD, the method comprising:

(a) determining the presence of a first risk factor by detecting an elevated level of an anti-flagellin antibody in a pre-operative sample from the subject relative to a level of the anti-flagellin antibody from an average subject with CD;

(b) determining the presence of a second risk factor by detecting the presence of perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) in the sample;

(c) determining the presence of a third risk factor by determining whether the subject is an active smoker;

(d) predicting a risk of post-operative recurrence of CD in the subject based upon the presence of the first, second, and third risk factors, wherein the recurrence of CD comprises endoscopic recurrence, histological recurrence, or clinical recurrence,

wherein the presence of one risk factor is predictive of an increased risk of post-operative recurrence of CD relative to an average subject with CD undergoing surgical treatment of the CD, wherein the presence of two of the risk factors is predictive of a greater risk of post-operative recurrence of CD relative to the presence of one of the risk factors, and wherein the presence of three of the risk factors is predictive of greater risk of post-operative recurrence of CD relative to the presence of two of the risk factors; and

(e) providing a post-operative CD therapy to the subject based on the presence of one two or three of the risk factors.

2. The method of claim 1 , wherein the anti-flagellin antibody is selected from the group consisting of an anti-Fla2 antibody, an anti-FlaX antibody, and an anti-CBir1 antibody.

3. The method of claim 1 , wherein the anti-flagellin antibody comprises an anti-Fla2 antibody.

4. The method of claim 1 , wherein pANCA is positive.

5. The method of claim 1 , wherein the elevated level of the anti-flagellin antibody comprises greater than 66 EU/ml of the anti-flagellin antibody.

6. The method of claim 1 , wherein the post-operative recurrence comprises an endoscopic recurrence score of i3 or i4.

7. The method of claim 1 , wherein the surgical treatment comprises an intestinal resection.

8. The method of claim 1 , wherein the post-operative CD therapy comprises an additional surgical intervention.

9. The method of claim 1 , wherein the post-operative CD therapy comprises a prophylactic drug treatment.

10. A method for predicting post-operative recurrence of CD in a subject with CD that is undergoing or planning on undergoing surgical treatment of the CD, the method comprising:

(a) determining the presence of a first risk factor by detecting, by an immunoassay, a level of an anti-flagellin antibody greater than 66 EU/ml in a pre-operative sample from the subject;

(b) determining the presence of a second risk factor by detecting the presence of pANCA in the sample; and

(c) determining the presence of a third risk factor by determining whether the subject is an active smoker;

(d) predicting a risk of post-operative recurrence of CD in the subject based upon the presence of the first, second, and third risk factors, wherein the recurrence of CD comprises endoscopic recurrence, histological recurrence, or clinical recurrence,

wherein the presence of one risk factor is predictive of an increased risk of post-operative recurrence of CD relative to an average subject with CD undergoing surgical treatment of the CD, wherein the presence of two of the risk factors is predictive of a greater risk of post-operative recurrence of CD relative to the presence of one of the risk factors, and wherein the presence of three of the risk factors is predictive of greater risk of post-operative recurrence of CD relative to the presence of two of the risk factors.

11. The method of claim 10 , further comprising: (e) providing a post-operative CD therapy to the subject based on the presence of one, two, or three of the risk factors.

12. The method of claim 10 , wherein the post-operative recurrence comprises endoscopic recurrence.

13. The method of claim 10 , wherein the surgical treatment comprises an intestinal resection.

14. The method of claim 10 , wherein the anti-flagellin antibody comprises an anti-Fla2 antibody.

15. The method of claim 1 , wherein the sample comprises a serum sample.

16. The method of claim 10 , wherein the sample comprises a serum sample.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 056635/0750 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CHANGE OF NAME Recorded Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
To: PRECISION IBD, INC.
Reel/Frame 050166/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: FERRANTE, MARC; VERMIERE, SEVERINE
To: KATHOLIEKE UNIVERSITEIT LEUVEN
Reel/Frame 041282/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: LOCKTON, STEVEN; SINGH, SHARAT
To: NESTEC S.A.
Reel/Frame 041282/0332 →